β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy

Jessica J O'Konek; Shingo Kato; Satomi Takao; Liat Izhak; Zheng Xia; Petr Illarionov; Gurdyal S Besra; Masaki Terabe; Jay A Berzosfky

doi:10.1158/1078-0432.CCR-12-2169

β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy

Jessica J O'Konek, Shingo Kato, Satomi Takao, Liat Izhak, Zheng Xia, Petr Illarionov, Gurdyal S Besra, Masaki Terabe, Jay A Berzosfky

Biosciences

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Most studies characterizing antitumor properties of iNKT cells have used the agonist, α-galactosylceramide (α-GalCer). However, α-GalCer induces strong, long-lasting anergy of iNKT cells, which could be a major detriment for clinical therapy. A novel iNKT cell agonist, β-mannosylceramide (β-ManCer), induces strong antitumor immunity through a mechanism distinct from that of α-GalCer. The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells.

Original language	English
Journal	Clinical Cancer Research
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-2169
Publication status	Published - 26 Jun 2013

Access to Document

10.1158/1078-0432.CCR-12-2169

Design, synthesis, and assessment of specific iNKT cell agonists for clinical applications
Besra, D., Cox, L., Cunningham, A. & Lammas, T.
Medical Research Council
1/03/12 → 29/02/16
Project: Research Councils

Cite this

@article{b0a94452ea2746ec877bb6c8950d7cf5,

title = "β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy",

abstract = "Most studies characterizing antitumor properties of iNKT cells have used the agonist, α-galactosylceramide (α-GalCer). However, α-GalCer induces strong, long-lasting anergy of iNKT cells, which could be a major detriment for clinical therapy. A novel iNKT cell agonist, β-mannosylceramide (β-ManCer), induces strong antitumor immunity through a mechanism distinct from that of α-GalCer. The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells.",

author = "O'Konek, {Jessica J} and Shingo Kato and Satomi Takao and Liat Izhak and Zheng Xia and Petr Illarionov and Besra, {Gurdyal S} and Masaki Terabe and Berzosfky, {Jay A}",

year = "2013",

month = jun,

day = "26",

doi = "10.1158/1078-0432.CCR-12-2169",

language = "English",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

}

TY - JOUR

T1 - β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy

AU - O'Konek, Jessica J

AU - Kato, Shingo

AU - Takao, Satomi

AU - Izhak, Liat

AU - Xia, Zheng

AU - Illarionov, Petr

AU - Besra, Gurdyal S

AU - Terabe, Masaki

AU - Berzosfky, Jay A

PY - 2013/6/26

Y1 - 2013/6/26

N2 - Most studies characterizing antitumor properties of iNKT cells have used the agonist, α-galactosylceramide (α-GalCer). However, α-GalCer induces strong, long-lasting anergy of iNKT cells, which could be a major detriment for clinical therapy. A novel iNKT cell agonist, β-mannosylceramide (β-ManCer), induces strong antitumor immunity through a mechanism distinct from that of α-GalCer. The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells.

AB - Most studies characterizing antitumor properties of iNKT cells have used the agonist, α-galactosylceramide (α-GalCer). However, α-GalCer induces strong, long-lasting anergy of iNKT cells, which could be a major detriment for clinical therapy. A novel iNKT cell agonist, β-mannosylceramide (β-ManCer), induces strong antitumor immunity through a mechanism distinct from that of α-GalCer. The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells.

U2 - 10.1158/1078-0432.CCR-12-2169

DO - 10.1158/1078-0432.CCR-12-2169

M3 - Article

C2 - 23804426

SN - 1078-0432

JO - Clinical Cancer Research

JF - Clinical Cancer Research

ER -

β-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy

Abstract

Access to Document

Fingerprint

Projects

Design, synthesis, and assessment of specific iNKT cell agonists for clinical applications

Cite this